Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

46.92 UNCHANGED
Streaming Delayed Price Updated: 12:42 PM EDT, Aug 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 158,375
Open 47.16
Bid (Size) 46.89 (1)
Ask (Size) 46.94 (1)
Prev. Close 46.92
Today's Range 46.60 - 47.16
52wk Range 35.95 - 54.44
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
Via Benzinga
12 Analysts Have This To Say About Ionis Pharmaceuticals
Via Benzinga

Performance

YTD
-11.25%
-11.25%
1 Month
-8.80%
-8.80%
3 Month
+24.65%
+24.65%
6 Month
+1.78%
+1.78%
1 Year
+14.83%
+14.83%

More News

Read More
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Via Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
Via Investor's Business Daily
The Latest Analyst Ratings For Ionis Pharmaceuticals
Via Benzinga
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
Via Benzinga
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
Via Benzinga
The Latest Analyst Ratings For Ionis Pharmaceuticals
Via Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Masters In Trading - Saturday, June 22
Via Talk Markets
Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
Via Benzinga
Exposures Product Safety
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
Via Benzinga
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals
Via Benzinga
Earnings Scheduled For February 21, 2024
Via Benzinga
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
From Biogen Inc.
Via GlobeNewswire
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
Via InvestorPlace
IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
Via Benzinga
Are These 5 Undervalued Stocks Ready to Break Out?
Via MarketBeat
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
From Biogen Inc.
Via GlobeNewswire
JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
Via Benzinga
Exposures Product Safety
Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.